17 February 2017
Rhythm reaches mezzanine stage to raise $41m
Pfizer and Ipsen returned to reinvest in the metabolic disorder treatment developer, which has now raised $114m altogether.
Author: Robert Lavine, News Editor
US-based peptide therapeutics developer Rhythm closed a $41m mezzanine round yesterday that included pharmaceutical companies Pfizer and Ipsen, the former participating through its Pfizer Venture Investments unit.